Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neo-CRCVAS
- Development stage
- Preclinical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Unknown
01
Overview
Neo-CRCVAS is a personalized neoantigen vaccine developed using whole-exome and RNA sequencing of murine microsatellite stable colorectal cancer (MSS-CRC) cells. The vaccine comprises a panel of seven immunogenic neoantigens specific to the tumor, selected for their ability to elicit a tumor-specific immune response. Neo-CRCVAS functions as an immunotherapeutic agent designed to stimulate the host's immune system to recognize and attack colorectal cancer cells by presenting tumor-associated neoantigen peptides. It has primarily been tested in combination with regorafenib in preclinical models to boost anti-tumor efficacy, termed "RegoNeo." Mechanism involves antigen presentation and induction of a T-cell mediated immune response against tumor-specific neoantigen epitopes.[2][3]
- Brand names
- Neo-CRCVAS
- Other names
- Neo-CRCVAS
02
Targets
MHC I (MHC class I})Neoantigen-specific T-cell receptor
Beyond the preview
Go deeper on Neo-CRCVAS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neo-CRCVAS.